Like much of the federal government, the Food and Drug Administration has faced several program cuts and changes under the Trump administration’s sweeping changes to the bureaucracy.

In the most recent round of cuts, various senior negotiators at the FDA who talk with pharmaceutical companies to renew user fee programs that fund the drug review system were laid off, per a report from Reuters.

The report claims the 15 people who were fired included the head negotiator and deputy negotiator for one of the user fee agreements, which could set back the reauthorization of agreements.

Another part of the FDA that has seen cuts is its Division of Food Processing Science and Technology, with a report from Bloomberg claiming 15 to 20 division workers lost their jobs. The researchers worked on reducing contamination in powdered baby formula.

The FDA is also reportedly looking to cut aspects of the food safety inspection program, according to a report from CBS News. The preliminary plans, which may require Congressional approval, could shift more of the inspections to states or local officials. The FDA already outsources some of its inspections to states through contracts.

Reports have swirled about cuts to various FDA departments. The Department of Health and Human Services, which oversees the agency, is seeking up to $35 billion in cuts to its budget for fiscal 2026, according to a preliminary document.

OMB DRAFTS PROPOSAL TO CUT $35 BILLION IN HHS FUNDING

The 64-page budget request draft from the Office of Management and Budget outlined cuts to various federal programs that focus on autism, drug abuse, and mental health, while also merging many agencies and programs for greater efficiency. An OMB spokesperson told Politico that “no final funding decisions have been made” with the preliminary document.

HHS Secretary Robert F. Kennedy Jr. has seen significant shake-ups as he works to implement his “Make America Healthy Again” agenda, seeking to cut out significant amounts of bureaucracy within the agency.

The Washington Examiner has reached out to the FDA.